强化降脂对缺血性脑卒中患者血清白介素-6、8和10水平的影响及疗效观察

Influence and curative effect observation of intensive lipid-lowering on serum interleukin-6, 8 and 10(IL-6, 8 and 10) levels of patients with cerebral arterial thrombosis

目的探讨强化降脂对缺血性脑卒中患者血清白介素-6、8和10水平的影响及疗效观察。方法将88例缺血性脑卒中患者随机分为强化组(n=44)和普通组(n=44)。两组均予以降颅内压、控制血压和血糖、抗血小板聚集及营养脑细胞等治疗。普通组加用阿托伐他汀片口服,20 mg/次,1次/d;强化组加用阿托伐他汀片口服,40 mg/次,1次/d,两组连用4周。观察并记录两组治疗前和治疗2周和4周后血清IL-6、8和10水平变化,并比较其疗效及不良反应。结果治疗2周和4周后,两组血清IL-6、8水平较前明显下降,IL-10水平较前明显上升(P<0.05或P<0.01),且强化组下降或上升值明显大于普通组(P<0.05);同时治疗4周后强化组临床总有效率明显高于普通组(χ2=5.09,P<0.05),两组治疗中未发生明显药物不良反应。结论阿托伐他汀强化降脂治疗缺血性脑卒中疗效确切,安全性较好,与其能降低血清IL-6、8水平和上调血清IL-10水平及纠正血清炎症因子网络紊乱密切相关。

Objective To discuss the influence and curative effect of intensive lipid-lowering on serum Interleukin-6, 8 and 10﹙IL-6, 8 and 10） levels of patients with cerebral arterial thrombosis. Methods A total of 88 cases of patients with cerebral arterial thrombosis were selected and divided into intensive group ﹙n=44） and ordinary group ﹙n=44） at random. The patients in two groups were promptly given routine lowering intracranial pressure, control of blood pres-sure and blood sugar, anti-platelet aggregation, brain cells nutrition and other medical treatment. The patients in ordi-nary group were additionally given Atorvastatin tablets through the mouth, 20 mg per time, once a day, and the patients in intensive group were additionally given Atorvastatin tablets through the mouth, 40 mg per time, once a day for 4 weeks. The changes of serum IL-6, 8 and 10 levels of patients in two groups before and 2 or 4 weeks after medical treatment were observed and recorded, and the clinical curative effect and drug adverse reaction﹙DAR） were compared as well. Results After 2 or 4 weeks’medical treatment, the serum IL-6 and 8 levels of patients in two groups obviously declined than before, while the IL-10 levels obviously rose than before ﹙P〈0.05 or P〈0.01）, and the declining or rising rates of patients in intensive group were much higher than those in ordinary group ﹙P〈0.05）. Meanwhile, the total clinical efficiency of patients in intensive group was much higher than that in ordinary group after 2 or 4 weeks’medi-cal treatment ﹙χ^2=5.09, P〈0.05）. No obvious DAR appeared on patients in two groups during the medical treatment. Conclusion Atorvastatin intensive lipid-lowering has reliable curative effect on cerebral arterial thrombosis with high security, whose mechanism of action has close effect on reducing the serum IL-6 and 8 levels, raising serum IL-10 level, adjusting the serum inflammatory cytokines network disorder.